BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen S, Liu Y, Niu Y, Xu Y, Zhou Q, Xu X, Wang J, Yu M. Increased abundance of myeloid-derived suppressor cells and Th17 cells in peripheral blood of newly-diagnosed Parkinson's disease patients. Neurosci Lett 2017;648:21-5. [PMID: 28359932 DOI: 10.1016/j.neulet.2017.03.045] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Wallings RL, Herrick MK, Tansey MG. LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson's. Front Neurosci 2020;14:443. [PMID: 32508566 DOI: 10.3389/fnins.2020.00443] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
2 Pawelec G, Verschoor CP, Ostrand-Rosenberg S. Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity. Front Immunol 2019;10:1099. [PMID: 31156644 DOI: 10.3389/fimmu.2019.01099] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 18.3] [Reference Citation Analysis]
3 Zhou C, Zhou X, He D, Li Z, Xie X, Ren Y. Reduction of Peripheral Blood iNKT and γδT Cells in Patients With Parkinson's Disease: An Observational Study. Front Immunol 2020;11:1329. [PMID: 32670293 DOI: 10.3389/fimmu.2020.01329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Izvolskaia M, Sharova V, Zakharova L. Perinatal Inflammation Reprograms Neuroendocrine, Immune, and Reproductive Functions: Profile of Cytokine Biomarkers. Inflammation 2020;43:1175-83. [PMID: 32279161 DOI: 10.1007/s10753-020-01220-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Park J, Kim CH. Regulation of common neurological disorders by gut microbial metabolites. Exp Mol Med 2021. [PMID: 34857900 DOI: 10.1038/s12276-021-00703-x] [Reference Citation Analysis]
6 Lee JH, Han K, Gee HY. The incidence rates and risk factors of Parkinson disease in patients with psoriasis: A nationwide population-based cohort study. J Am Acad Dermatol 2020;83:1688-95. [PMID: 31302182 DOI: 10.1016/j.jaad.2019.07.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Prots I, Winner B. Th17 cells: a promising therapeutic target for Parkinson's disease? Expert Opin Ther Targets 2019;23:309-14. [PMID: 30871383 DOI: 10.1080/14728222.2019.1590336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
8 Yan Z, Yang W, Wei H, Dean MN, Standaert DG, Cutter GR, Benveniste EN, Qin H. Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease. Neurol Neuroimmunol Neuroinflamm 2021;8:e1036. [PMID: 34301818 DOI: 10.1212/NXI.0000000000001036] [Reference Citation Analysis]
9 Jin M, Akgün K, Ziemssen T, Kipp M, Günther R, Hermann A. Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs. Int J Mol Sci 2021;22:8042. [PMID: 34360808 DOI: 10.3390/ijms22158042] [Reference Citation Analysis]
10 Bhatia D, Grozdanov V, Ruf WP, Kassubek J, Ludolph AC, Weishaupt JH, Danzer KM. T-cell dysregulation is associated with disease severity in Parkinson's Disease. J Neuroinflammation 2021;18:250. [PMID: 34717679 DOI: 10.1186/s12974-021-02296-8] [Reference Citation Analysis]
11 Campos-Acuña J, Elgueta D, Pacheco R. T-Cell-Driven Inflammation as a Mediator of the Gut-Brain Axis Involved in Parkinson's Disease. Front Immunol 2019;10:239. [PMID: 30828335 DOI: 10.3389/fimmu.2019.00239] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
12 Pawelec G, Picard E, Bueno V, Verschoor CP, Ostrand-Rosenberg S. MDSCs, ageing and inflammageing. Cell Immunol 2021;362:104297. [PMID: 33550187 DOI: 10.1016/j.cellimm.2021.104297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Griffiths JI, Wallet P, Pflieger LT, Stenehjem D, Liu X, Cosgrove PA, Leggett NA, McQuerry JA, Shrestha G, Rossetti M, Sunga G, Moos PJ, Adler FR, Chang JT, Sharma S, Bild AH. Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. Proc Natl Acad Sci U S A 2020;117:16072-82. [PMID: 32571915 DOI: 10.1073/pnas.1918937117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
14 Budhwar S, Verma P, Verma R, Rai S, Singh K. The Yin and Yang of Myeloid Derived Suppressor Cells. Front Immunol 2018;9:2776. [PMID: 30555467 DOI: 10.3389/fimmu.2018.02776] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 8.8] [Reference Citation Analysis]
15 Álvarez-Luquín DD, Arce-Sillas A, Leyva-Hernández J, Sevilla-Reyes E, Boll MC, Montes-Moratilla E, Vivas-Almazán V, Pérez-Correa C, Rodríguez-Ortiz U, Espinoza-Cárdenas R, Fragoso G, Sciutto E, Adalid-Peralta L. Regulatory impairment in untreated Parkinson's disease is not restricted to Tregs: other regulatory populations are also involved. J Neuroinflammation 2019;16:212. [PMID: 31711508 DOI: 10.1186/s12974-019-1606-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
16 Rostami J, Fotaki G, Sirois J, Mzezewa R, Bergström J, Essand M, Healy L, Erlandsson A. Astrocytes have the capacity to act as antigen-presenting cells in the Parkinson's disease brain. J Neuroinflammation 2020;17:119. [PMID: 32299492 DOI: 10.1186/s12974-020-01776-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
17 Roversi K, Callai-Silva N, Roversi K, Griffith M, Boutopoulos C, Prediger RD, Talbot S. Neuro-Immunity and Gut Dysbiosis Drive Parkinson's Disease-Induced Pain. Front Immunol 2021;12:759679. [PMID: 34868000 DOI: 10.3389/fimmu.2021.759679] [Reference Citation Analysis]
18 Chen Z, Chen S, Liu J. The role of T cells in the pathogenesis of Parkinson's disease. Prog Neurobiol 2018;169:1-23. [PMID: 30114440 DOI: 10.1016/j.pneurobio.2018.08.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
19 Li D, Mastaglia FL, Fletcher S, Wilton SD. Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era. Med Res Rev 2020;40:2650-81. [PMID: 32767426 DOI: 10.1002/med.21718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
20 Thome AD, Atassi F, Wang J, Faridar A, Zhao W, Thonhoff JR, Beers DR, Lai EC, Appel SH. Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson's disease. NPJ Parkinsons Dis 2021;7:41. [PMID: 33986285 DOI: 10.1038/s41531-021-00188-5] [Reference Citation Analysis]
21 Machhi J, Kevadiya BD, Muhammad IK, Herskovitz J, Olson KE, Mosley RL, Gendelman HE. Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. Mol Neurodegener 2020;15:32. [PMID: 32503641 DOI: 10.1186/s13024-020-00375-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
22 Page MJ, Pretorius E. Platelet Behavior Contributes to Neuropathologies: A Focus on Alzheimer's and Parkinson's Disease. Semin Thromb Hemost 2021. [PMID: 34624913 DOI: 10.1055/s-0041-1733960] [Reference Citation Analysis]
23 Grotemeyer A, McFleder RL, Wu J, Wischhusen J, Ip CW. Neuroinflammation in Parkinson's Disease - Putative Pathomechanisms and Targets for Disease-Modification. Front Immunol 2022;13:878771. [PMID: 35663989 DOI: 10.3389/fimmu.2022.878771] [Reference Citation Analysis]
24 Su R, Zhou T. Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson's Disease. Front Aging Neurosci 2021;13:769506. [PMID: 34803660 DOI: 10.3389/fnagi.2021.769506] [Reference Citation Analysis]
25 He Y, Peng K, Li R, Zhang Z, Pan L, Zhang T, Lin A, Hong R, Nie Z, Guan Q, Jin L. Changes of T lymphocyte subpopulations and their roles in predicting the risk of Parkinson's disease. J Neurol 2022. [PMID: 35608657 DOI: 10.1007/s00415-022-11190-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Storelli E, Cassina N, Rasini E, Marino F, Cosentino M. Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence. Front Neurol 2019;10:13. [PMID: 30733703 DOI: 10.3389/fneur.2019.00013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
27 Garretti F, Agalliu D, Lindestam Arlehamn CS, Sette A, Sulzer D. Autoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells. Front Immunol 2019;10:303. [PMID: 30858851 DOI: 10.3389/fimmu.2019.00303] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 17.7] [Reference Citation Analysis]
28 Salminen A, Kaarniranta K, Kauppinen A. The potential importance of myeloid-derived suppressor cells (MDSCs) in the pathogenesis of Alzheimer’s disease. Cell Mol Life Sci 2018;75:3099-120. [DOI: 10.1007/s00018-018-2844-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
29 Baird JK, Bourdette D, Meshul CK, Quinn JF. The key role of T cells in Parkinson's disease pathogenesis and therapy. Parkinsonism Relat Disord 2019;60:25-31. [PMID: 30404763 DOI: 10.1016/j.parkreldis.2018.10.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
30 Sommer A, Winner B, Prots I. The Trojan horse - neuroinflammatory impact of T cells in neurodegenerative diseases. Mol Neurodegener 2017;12:78. [PMID: 29078813 DOI: 10.1186/s13024-017-0222-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]